Hepatitis A virus purified and triply cloned

US4620978A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Richard J. Daemer · Washington, US
• Stephen M. Feinstone · Boyds, US
• Ian D. Gust · Parramatta, AU
• Robert H. Purcell · Boyds, US

Key dates

• Filing date: Sep 19, 1984
• Grant date: Nov 4, 1986
• Expiry date: Sep 19, 2004

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human hepatitis A virus (HAV) can be purified by a process in which master seed lots of HM-175 strain of hepatitis A virus are prepared from triply cloned virus by terminal dilution at passage level about 20 or preferably at least 20-30. The clones tested induced minimal or no hepatitis although significant antibody response was provoked in inoculated primates. A method of preparing the triply cloned inoculum is also described.